GILD Q call- typical no slides | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11903 of 11927  at  2/4/2020 5:39:58 PM  by

spaddy


 In response to msg 11902 by  mymorningsong
view thread

Re: GILD Q call- typical no slides

 Thanks..link wasn't on the earnings presentation page when I had looked..
 
Seems like KTE-X19 is separated out vs axi-cel trials, so I guess they will name it something different than Yescarta when launched?
Only difference is its manufactured differently?
 
3 preclinical CART trials using different mechanisms
 
Allogenic CART cd19 vs DLBCL
Anti CLL-1 vs AML
Dual antigen vs DLBCL
 
So looks like they focusing on DLBCL target again even though Yescarta does that.
Likely since they have the most data in those indications to make the best upgraded drugs.
Nice safe way to make your first allogenic product by making an allogenic Yescarta.
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 133
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...